ATE319996T1 - Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin - Google Patents

Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin

Info

Publication number
ATE319996T1
ATE319996T1 AT00981763T AT00981763T ATE319996T1 AT E319996 T1 ATE319996 T1 AT E319996T1 AT 00981763 T AT00981763 T AT 00981763T AT 00981763 T AT00981763 T AT 00981763T AT E319996 T1 ATE319996 T1 AT E319996T1
Authority
AT
Austria
Prior art keywords
mortalin
cure
finding
cancer
interaction domain
Prior art date
Application number
AT00981763T
Other languages
English (en)
Inventor
Renu Chugai Wadhwa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE319996T1 publication Critical patent/ATE319996T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00981763T 1999-12-16 2000-12-15 Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin ATE319996T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35754599 1999-12-16

Publications (1)

Publication Number Publication Date
ATE319996T1 true ATE319996T1 (de) 2006-03-15

Family

ID=18454687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981763T ATE319996T1 (de) 1999-12-16 2000-12-15 Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin

Country Status (6)

Country Link
US (1) US20030087263A1 (de)
EP (1) EP1243923B1 (de)
AT (1) ATE319996T1 (de)
AU (1) AU1891801A (de)
DE (1) DE60026576T2 (de)
WO (1) WO2001044807A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295976A1 (de) 2003-03-08 2011-03-16 Auvation Ltd Marker für Darmkrebs
EP1536230A1 (de) * 2003-11-28 2005-06-01 Deutsches Rheuma-Forschungszentrum Berlin Durchflusszytometrischer Partikel-basierter Bindungsassay
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
EP2819688A4 (de) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazol- und thioethervernetzte peptidomimetische makrozyklen
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2906954B1 (de) * 2012-10-09 2018-04-11 Ramot at Tel-Aviv University Ltd. Verfahren und kits zur prognose von krebs unter verwendung von löslichem mortalin im blut
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (de) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7445800A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Method of prolonging normal cell life span
WO2001088104A2 (en) * 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations
JP2001354564A (ja) * 2000-06-14 2001-12-25 Chugai Bunshi Igaku Kenkyusho:Kk カチオン性ローダシアニン系色素誘導体を有効成分とする、ｍｏｔ−２蛋白質とｐ５３蛋白質の相互作用阻害剤

Also Published As

Publication number Publication date
US20030087263A1 (en) 2003-05-08
DE60026576D1 (de) 2006-05-04
WO2001044807A1 (en) 2001-06-21
DE60026576T2 (de) 2007-01-18
EP1243923B1 (de) 2006-03-08
EP1243923A4 (de) 2004-05-06
AU1891801A (en) 2001-06-25
EP1243923A1 (de) 2002-09-25

Similar Documents

Publication Publication Date Title
ATE319996T1 (de) Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin
EP2261246A3 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
CY1110549T1 (el) Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης
ATE555202T1 (de) Verfahren zur lieferung von rna-interferenz und verwendungen damit
WO2005111066A3 (en) Polypeptides from non-typeable haemophilus influenzae
WO2020198264A8 (en) Modified cleavases, uses thereof and related kits
ATE343788T1 (de) Verfahren zum simultanen nachweis von beiden gliedern eines bindungspaares
DE60133982D1 (de) Biosensor und verfahren zum analysieren von blutkomponenten
ATE420366T1 (de) ERWEITERTER ßTETHERINGß ANSATZ ZUM SCHNELLEN AUFFINDEN VON LIGANDEN
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
DK1705183T3 (da) Bindingsmolekyler for human faktor VIII og faktor VIII-lignende proteiner
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
DE60206173D1 (de) Härtende zusammensetzung und verfahren zum aufbringen von alkydbeschichtungsmaterial damit
WO2003002724A3 (en) Proteins, druggable regions of proteins and target analysis for chemistry of therapeutics
DE602004032345D1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
DE60213900D1 (de) Bolzen und diesen verwendendes Verfahren zum Spannen von Bauteilen
ATE223491T1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DE69924120D1 (de) Für ataxin-2-bindende proteine kodierende nukleinsäure, damit verwandten produkten und verfahren zur deren anwendung
ATE284034T1 (de) Verfahren zum nachweis von protein s
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
ATE332916T1 (de) Farbstoff-markiertes peptid und dessen verwendung zur diagnostik
DE69804416D1 (de) Verfahren zur Konditionierung von organischen Pigmenten
DE60037330D1 (de) Verfahren zur spezifizitätsmodulierung von nitrilasen, nitrilasen aus diesem verfahren gewonnen und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties